GoAI
Get started
Towa Pharmaceutical Co., Ltd. logo

Towa Pharmaceutical Co., Ltd.

4553.T

JPXHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

¥3,890

−¥5.00 · -0.13%

Aug 24, 2:37 PM JST

4553.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
JP
CEO
Itsuro Yoshida
Listed since
Apr 5, 2004
Employees
4,923

Market position

Day range

Current ¥3,890

52-week range

Current ¥3,890

Open
¥3,895
Previous close
¥3,895
Volume
43.5K
0.32× average
Average volume
137.9K
Average daily volume
Market cap
191.5B JPY
Beta
-0.09
Market reference 1
50-day average
¥3,934.8
-1.14% below average
200-day average
¥3,810.09
+2.10% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
378.59B JPY
P/E (TTM)
23.16×
P/B (TTM)
1.05×
P/S (TTM)
0.68×
EV / EBITDA
9.89×
Earnings yield
2.66%
Free cash flow yield
4.13%
Dividend yield
2.06%

Profitability & efficiency

Gross margin
36.27%
Operating margin
8.72%
Net margin
2.95%
Return on equity
2.95%
Return on assets
1.10%
Return on invested capital
2.25%

Financial health

Debt / equity
1.26×
Current ratio
2.76×
Altman Z-score
1.98
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends47%30%13%-3%Gross margin, FY2022: 42.38%Gross margin, FY2023: 34.81%Gross margin, FY2024: 35.70%Gross margin, FY2025: 36.49%Gross margin, FY2026: 36.21%Operating margin, FY2022: 11.19%Operating margin, FY2023: 2.64%Operating margin, FY2024: 7.74%Operating margin, FY2025: 8.95%Operating margin, FY2026: 8.44%Net margin, FY2022: 9.61%Net margin, FY2023: 1.05%Net margin, FY2024: 7.10%Net margin, FY2025: 7.31%Net margin, FY2026: 1.92%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 42.38%. Gross margin FY2023 34.81%. Gross margin FY2024 35.70%. Gross margin FY2025 36.49%. Gross margin FY2026 36.21%. Operating margin FY2022 11.19%. Operating margin FY2023 2.64%. Operating margin FY2024 7.74%. Operating margin FY2025 8.95%. Operating margin FY2026 8.44%. Net margin FY2022 9.61%. Net margin FY2023 1.05%. Net margin FY2024 7.10%. Net margin FY2025 7.31%. Net margin FY2026 1.92%.

Income trends

Revenue

273.71B JPY+5.44%

Operating income

23.1B JPY-0.60%

Net income

5.25B JPY-72.35%
Income trends across reported periods300.86B JPY192.26B JPY83.65B JPY−24.95B JPYRevenue, FY2022: 165.62B JPYRevenue, FY2023: 208.86B JPYRevenue, FY2024: 227.93B JPYRevenue, FY2025: 259.59B JPYRevenue, FY2026: 273.71B JPYOperating income, FY2022: 18.54B JPYOperating income, FY2023: 5.52B JPYOperating income, FY2024: 17.65B JPYOperating income, FY2025: 23.24B JPYOperating income, FY2026: 23.1B JPYNet income, FY2022: 15.91B JPYNet income, FY2023: 2.2B JPYNet income, FY2024: 16.17B JPYNet income, FY2025: 18.99B JPYNet income, FY2026: 5.25B JPYFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 165.62B JPY. Revenue FY2023 208.86B JPY. Revenue FY2024 227.93B JPY. Revenue FY2025 259.59B JPY. Revenue FY2026 273.71B JPY. Operating income FY2022 18.54B JPY. Operating income FY2023 5.52B JPY. Operating income FY2024 17.65B JPY. Operating income FY2025 23.24B JPY. Operating income FY2026 23.1B JPY. Net income FY2022 15.91B JPY. Net income FY2023 2.2B JPY. Net income FY2024 16.17B JPY. Net income FY2025 18.99B JPY. Net income FY2026 5.25B JPY.
Metric (JPY)FY2026FY2025FY2024FY2023FY2022
Revenue273.71B JPY259.59B JPY227.93B JPY208.86B JPY165.62B JPY
Cost of goods sold174.61B JPY164.87B JPY146.55B JPY136.15B JPY95.43B JPY
Gross profit99.1B JPY94.73B JPY81.38B JPY72.71B JPY70.19B JPY
Research and development—16.21B JPY13.24B JPY15.27B JPY11.49B JPY
Selling, general, and administrative76B JPY55.27B JPY50.49B JPY51.93B JPY40.16B JPY
Operating expenses76B JPY71.49B JPY63.74B JPY67.2B JPY51.65B JPY
Interest income309M JPY221M JPY97M JPY17M JPY8M JPY
Interest expense2.26B JPY1.63B JPY947M JPY1.13B JPY230M JPY
Depreciation and amortization22.84B JPY20.1B JPY17.89B JPY19.41B JPY10.95B JPY
Operating income23.1B JPY23.24B JPY17.65B JPY5.52B JPY18.54B JPY
Net income5.25B JPY18.99B JPY16.17B JPY2.2B JPY15.91B JPY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
60%
6 beats, 4 misses, 0 met estimates
Average EPS surprise
+107.70%
10 comparable reports
Latest EPS result
112.36

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates213.7951.2-111.4-273.99Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26No estimateQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 163.93, estimate 57.66, surprise +184.30%, Beat. Q2 2025, reported May 15, 2025: actual 88.61, estimate 113.89, surprise -22.20%, Miss. Q3 2025, reported Aug 7, 2025: actual 51.06, estimate 63.46, surprise -19.54%, Miss. Q4 2025, reported Nov 10, 2025: actual 115.8, estimate 62.02, surprise +86.71%, Beat. Q1 2026, reported Feb 13, 2026: actual 180.15, estimate 73.56, surprise +144.90%, Beat. Q2 2026, reported May 14, 2026: actual -240.35, estimate 107.89, surprise -322.77%, Miss. Q3 2026, reported Aug 6, 2026: actual 112.36, estimate —, surprise —, Comparison unavailable. Q4 2026, reported Nov 16, 2026: actual —, estimate 101.18, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates78.53B73.06B67.6B62.13BQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 70.33B JPY, estimate 70.1B JPY, surprise +0.33%, Beat. Q2 2025, reported May 15, 2025: actual 65.86B JPY, estimate 69.34B JPY, surprise -5.02%, Miss. Q3 2025, reported Aug 7, 2025: actual 65.15B JPY, estimate 67.85B JPY, surprise -3.98%, Miss. Q4 2025, reported Nov 10, 2025: actual 65.33B JPY, estimate 66.38B JPY, surprise -1.58%, Miss. Q1 2026, reported Feb 13, 2026: actual 73.59B JPY, estimate 75.51B JPY, surprise -2.55%, Miss. Q2 2026, reported May 14, 2026: actual 69.65B JPY, estimate 74.45B JPY, surprise -6.45%, Miss. Q3 2026, reported Aug 6, 2026: actual 71.38B JPY, estimate 71.38B JPY, surprise +0.00%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate 70.9B JPY, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

¥80.00

2025 complete year+63.3% since 2021

2026 partial: ¥40.00

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Sep 29, 2026

¥40.00

Semi-Annual

Record Sep 30, 2026 · Payment Sep 29, 2026

DividendUpcoming

Ex-dividend Mar 30, 2027

¥45.00

Semi-Annual

Record Mar 31, 2027 · Payment Mar 30, 2027

Dividend

Ex-dividend Mar 30, 2026

¥40.00

Semi-Annual

Record Mar 31, 2026 · Payment Jun 25, 2026

Dividend

Ex-dividend Sep 29, 2025

¥40.00

Semi-Annual

Record Sep 30, 2025 · Payment Dec 1, 2025

Dividend

Ex-dividend Mar 28, 2025

¥40.00

Semi-Annual

Record Mar 31, 2025 · Payment Jun 26, 2025

Dividend

Ex-dividend Sep 27, 2024

¥30.00

Semi-Annual

Record Sep 30, 2024 · Payment Dec 2, 2024

4553.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,989

-0.31%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,817

+0.92%

HOYA Corporation logo

7741.T

HOYA Corporation

¥25,030

+0.54%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,280

+0.70%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,866.5

+1.16%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,405

+0.75%

ETFs holding 4553.T

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core TOPIX ETF logoiShares Core TOPIX ETF1475.T
Market value
266.03M
Weight
0.01%
AUM
2.89T JPY
Expense ratio
0.05%
Price / 1D
¥418.4+0.10%
Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
8.88M
Weight
0.00%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71+0.78%
Avantis International Small Cap Value ETF logoAvantis International Small Cap Value ETFAVDV
Market value
7.08M
Weight
0.04%
AUM
20.24B USD
Expense ratio
0.36%
Price / 1D
$111.95+1.06%
Vanguard FTSE Developed Markets ETF logoVanguard FTSE Developed Markets ETFVEA
Market value
5.99M
Weight
0.00%
AUM
315B USD
Expense ratio
0.03%
Price / 1D
$73.42+0.80%
iShares Core MSCI EAFE ETF logoiShares Core MSCI EAFE ETFIEFA
Market value
3.85M
Weight
0.00%
AUM
195.14B USD
Expense ratio
0.07%
Price / 1D
$100.85+0.86%
Dimensional - International Small Cap Value ETF logoDimensional - International Small Cap Value ETFDISV
Market value
3.63M
Weight
0.07%
AUM
5.23B USD
Expense ratio
0.42%
Price / 1D
$44.49+0.86%
Vanguard FTSE All-World ex-US Small-Cap ETF logoVanguard FTSE All-World ex-US Small-Cap ETFVSS
Market value
2.25M
Weight
0.02%
AUM
13.6B USD
Expense ratio
0.06%
Price / 1D
$160.06+0.43%
iShares MSCI EAFE Small-Cap ETF logoiShares MSCI EAFE Small-Cap ETFSCZ
Market value
2.24M
Weight
0.02%
AUM
13.28B USD
Expense ratio
0.40%
Price / 1D
$86.60+0.70%

Continue in GoAI

Research 4553.T

research.disclaimer